PF-07104091 + fulvestrant

PF-07104091 + fulvestrant is an investigational combination therapy being studied for the treatment of advanced or metastatic hormone receptor-positive (HR+), HER2-negative breast cancer and other solid tumors. PF-07104091 is a novel, selective inhibitor of cyclin-dependent kinase 2 (CDK2), developed by Pfizer, designed to block cell cycle progression in cancer cells that have become resistant to prior therapies such as CDK4/6 inhibitors. Fulvestrant is an estrogen receptor antagonist that binds to and degrades the estrogen receptor, thereby blocking estrogen-driven tumor growth. The combination aims to overcome resistance mechanisms in patients who have progressed on previous endocrine therapies and CDK4/6 inhibitors[1][3][4][5].

Other names

tegtociclib + fulvestrant